Kidney (Renal) Cancer

Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.

Latest Discoveries

Trial Watch: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Kidney (Renal) Cancer
Published
October 22, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Kidney (Renal) Cancer
Published
October 21, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Kidney (Renal) Cancer
Published
August 14, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Major Advances

Clinical Trials

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Regulatory status: InvestigationalResearch type: Registered later-phase trial
Cancer type
Kidney (Renal) Cancer
Trial identifier
NCT01575548
Trial phase
Phase 3
View trial details
Study design
Not specified in this summary
Population
Participants age 18 Years and older with Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7 who meet the study-specific registry eligibility criteria.
Last reviewed
2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status
Investigational
Last verified
2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Regulatory status: InvestigationalResearch type: Registered later-phase trial
Cancer type
Kidney (Renal) Cancer
Trial identifier
NCT04195750
Trial phase
Phase 3
View trial details
Study design
Not specified in this summary
Population
Participants age 18 Years and older with Carcinoma, Renal Cell who meet the study-specific registry eligibility criteria.
Last reviewed
2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status
Investigational
Last verified
2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Regulatory status: InvestigationalResearch type: Registered later-phase trial
Cancer type
Kidney (Renal) Cancer
Trial identifier
NCT04736706
Trial phase
Phase 3
View trial details
Study design
Not specified in this summary
Population
Participants age 18 Years and older with Carcinoma, Renal Cell who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14

Regulatory status by jurisdiction

Country or region not specified

Status
Investigational
Last verified
2026-08-14

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Personalized neoantigen vaccine shows no cancer recurrence in small phase 1 kidney cancer trial

Regulatory status: InvestigationalResearch type: Early studies in people
Cancer type
Kidney (Renal) Cancer
Trial identifier
NCT02950766
View trial details
Study design
Non-randomized trial
Population
Adults with high-risk, fully surgically resected clear cell renal cell carcinoma (stage III or IV, no remaining visible cancer after surgery), given a personalized neoantigen vaccine with or without ipilimumab in the adjuvant (post-surgery, preventive) setting, in a phase 1, first-in-human trial.
Last reviewed
2026-08-13

Regulatory status by jurisdiction

Country or region not specified

Status
Investigational
Last verified
2026-08-13

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Refine your search

Related resources

Trusted resources: official cancer information

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.